1. Pluri expands agreement with Remedy Cell for cell-free therapeutics production. 2. PluriCDMO™ confirmed process scalability through engineering runs and clinical-grade batches. 3. Remedy Cell's lead candidate is set for its Phase 1b clinical trial. 4. The partnership enhances Pluri's capacity in regulatory-compliant manufacturing solutions. 5. Both companies aim to advance innovative therapies for fibrotic conditions.
FAQ
Why Bullish?
The expanded collaboration with Remedy Cell enhances Pluri's market position, similar to historical biotech partnerships that drove share prices positively.
How important is it?
The significance of the collaboration with Remedy Cell and its implications on PLUR's operations have high potential influence on stock price.
Why Short Term?
The upcoming clinical trials of Remedy Cell's product can yield near-term investor interest and market activity.
Pluri Expands Collaboration with Remedy Cell, Achieving Key Manufacturing Milestone
HAIFA, Israel, December 22, 2025 (GLOBE NEWSWIRE) - Pluri, Inc. (“Pluri”, Nasdaq, TASE: PLUR), a pioneering biotechnology company focused on cell-based solutions, has announced a significant expansion of its existing manufacturing agreement with Remedy Cell Ltd. (“Remedy Cell”), a biopharmaceutical company specializing in stem cell-derived therapeutics for fibrotic diseases. This enhancement in collaboration aims to further progress their joint mission of providing innovative therapeutic options.
Manufacturing Achievements: Successful Engineering Runs and Clinical-Grade Production
Under the terms of the expanded agreement, Pluri’s Contract Development and Manufacturing Organization (CDMO), known as PluriCDMO™, has successfully integrated Remedy Cell’s proprietary manufacturing process into its state-of-the-art Good Manufacturing Practice (GMP) facility. Significant accomplishments include:
- Completion of comprehensive GMP training for Remedy Cell's manufacturing team.
- Execution of engineering runs validating process robustness and scalability.
- Manufacturing of multiple clinical-grade batches of Remedy Cell’s lead candidate, intended for their initial Phase 1b clinical trial.
This collaborative achievement underscores the effective synergy between Remedy Cell’s innovative therapeutic platform and Pluri’s advanced manufacturing capabilities.
Broadened Collaboration: A Shared Vision for Cell-Free Therapeutics
The recent success has led Pluri and Remedy Cell to broaden the scope of their partnership. PluriCDMO™ will provide further manufacturing and process development support as Remedy Cell progresses through its clinical and pre-commercial stages. This expansion reinforces the commitment of both teams to advance cell-free biologics, addressing significant unmet medical needs.
Ayelet Dilion-Mashiah, CEO of Remedy Cell, remarked, “Working with Pluri has been highly productive. Their expertise has been invaluable in helping us reach this critical milestone.”
Yaky Yanay, CEO and President of Pluri, added, “We are proud to strengthen our agreement with Remedy Cell. This success positions PluriCDMO™ as a trusted partner for developing complex, cell-derived therapies.”
About Pluri Inc. and Remedy Cell Ltd.
Pluri Inc. is dedicated to pioneering advancements in mass-scale cell expansion and biofarming, utilizing its patented 3D cell expansion platform to develop effective, scalable solutions. With a focus on regenerative medicine and biomanufacturing, Pluri is committed to addressing global challenges.
Remedy Cell Ltd. is a clinical-stage biopharmaceutical company revolutionizing the treatment of fibrotic diseases through cell-derived, cell-free therapies. Its proprietary Activated Remedy Cell Secretome (ARcS) platform targets complex fibrotic conditions, including its lead product, RC-0315, designed to treat Idiopathic Pulmonary Fibrosis (IPF), a serious condition affecting millions worldwide.
Forward-Looking Statements
This announcement contains forward-looking statements regarding Pluri’s and Remedy Cell’s expectations for clinical trials and development programs. Actual results may differ significantly due to various factors, including market dynamics and regulatory challenges.